Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Motorola Solutions Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.4 (market cap $2.81B), while Motorola Solutions Inc trades at $458.35 (market cap $74.76B). The key difference: Motorola Solutions Inc is far larger — about 26.6× Dyne Therapeutics Inc. Common Stock's market cap, and Motorola Solutions Inc pays a 1.07% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Motorola Solutions Inc for 101 Days on average.
| DYN | MSI | |
|---|---|---|
Market Cap | $2.81B | $74.76B |
Volume | 2,195,902 | 541,174 |
Sector | Health | Technology |
52-Week High | $26.78 | $491.24 |
52-Week Low | $14.60 | $363.83 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $2.13B | $83.67B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Motorola Solutions (MSI) trades at $449.01, up 0.64% with a neutral technical signal. The company demonstrates strong fundamentals with consistent earnings beats, record $15.6B backlog (Zacks, 2026-09-28), and expanding profit margins. Recent acquisitions including D-Fend Solutions and DeepNeuronic enhance its defense and AI capabilities. Revenue growth accelerated to 11.7B in 2025 with net income margin improving to 18.43%.
MSI presents a compelling growth story with analyst consensus target of $525.86 (24/34 analysts rate Buy). Key risks include elevated valuation multiples (P/E 35.6) and significant capital expenditures driving negative cash flow. The stock offers 17% upside potential but requires monitoring of acquisition integration and defense spending cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
